Printer Friendly

Hemostatical activity of new benzylammonium salt 2-[3-methyl-1-n-propyl-7-(1,1-dioxotiethanyl-3)xantinyl-8-thio]acetic acid.


Preventing and stopping the bleeding is essential in various areas of clinical medicine, especially in hematology, [1] surgery, [2] traumatology, [3] oncology, [4] and tocology, [5] in view of the increasing number of patients with hemorrhagic manifestations, extensive use of anticoagulants (heparins and a number of coumarin drugs). [6]

Clinical experience shows that when planning surgical interventions with the integrity of the main arteries and veins, the capillary parenchymal hemorrhages are the primary sources of surgery blood loss. [7] To control them is achieved by local hypothermia using thermal and ultrasonic coagulation, [8] parenterally injecting fresh frozen plasma and its products, factors of blood clotting (isolated or in various combinations), aminocaproic acid, serine proteinase inhibitors (aprotinin), etamsylate, desmopressin, and several other drugs with different mechanisms of bleeding control. [9-13] Rationale of this research relates to the fact that the drugs traditionally used in medical practice to control bleeding are often inefficient and unable to lead to an effective reduction of blood loss which is dangerous due to the possible development of hemorrhagic shock, coagulopathy, ischemia, and the development of multiple organ failure. Overview of clinical recommendations show that among synthetic systemic hemostatic drugs the highly proved efficacy was confirmed only for tranexamic acid, aminocaproic acid, and etamsylate. [14] Most of hemostatic drugs are presented by fresh frozen plasma or recombinant factors, [15] the use of which is regulated by strict endeixes and is associated with high financial costs and the likelihood of complications and/or adverse effects. [16]

One of the ways to find new methods of bleeding prophylaxis is to develop means of pharmacological correction of hemostasis system. The results of the previous research show potentially high activity of some new nitrogen-containing heterocyclic derivatives regarding hemostasis system in vitro and in vivo. [17-19] This research is devoted to the study of hemostatic systemic activity of benzylammonium salt 2-[3-methyl-1-N-propyl-7-(1,1-dioxothietanil-3)xantinyl-8-thio]acetic acid (Figure 1) under experimental conditions. [20]


Design of the Research

All research work has been carried out in two phases; [21] the first phase examined the impact of Compound I on the hemostasis system in vitro. Then, the research rated systemic hemostatic activity of Compound I under bleeding conditions on intraperitoneal injection to rats. Under in vitro conditions, the study of the effect on the functional activity of platelets began with concentration of 2 x [10.sup.-3] mol/L, coagulation hemostasis component - [10.sup.-3] g/L, gradually reducing the concentration. Under in vivo conditions, rats were intraperitoneally injected with the test substances in equimolar concentration which for etamsylate was 38.1 mg/kg, for the Compound I is 73.8 mg/kg.

Experimental work in vitro is performed on blood of 54 male donors aged 18-24. The study was approved by Ethics Committee of State-Financed Educational Institution of Higher Professional Education "Bashkir State Medical University" of Health Ministry of Russia (No. 2 Dated from 17.10.2012). An informed consent was obtained from all research participants before blood sampling.

Experimental research in vivo is performed on 50 lab rats in compliance with the International recommendations of the European Convention for protection of vertebrate animals in experimental animals, laboratory practice regulations on conducting preclinical studies in Russia (GOST 51000.3-96 3 and 51000.4-96, GOSTR 50258-92) and the order of the Ministry of Health and Social development of Russia No. 708 n dated from 23/08/2010 "on approval of the rules for laboratory practice" (good laboratory practice). The animals were kept in standard conditions of animal quarters with natural lighting, air temperature of 20 [+ or -] 2[degrees]C and humidity of 55-60% in plastic cages with bedding from sawdust. 24 h before the research the feeding was stopped without limiting the access to water.

Blood Collection and Centrifugation

Blood sampling from donor volunteers was carried out from cubital vein using the systems of vacuum blood sampling BD Vacutainer[R] blood collection (Dickinson and Company, United States). The stage of working with laboratory animals included their anesthesia with diethylether, fixation on a peeling block and blood sampling from the jugular vein into siliconized tubes. Venous blood was stabilized by 3.8% sodium citrate solution in a ratio of 9:1.

All tests were carried out on enriched and platelet depleted dry blood. Samples of platelet-rich plasma were obtained by centrifuging the citrated blood with 100 g during 10 min, plateletless plasma - with 300 g during 15 min. The work included centrifuge OPN-3.02 (OJSC TNC "DASTAN", Kyrgyzstan).

Platelet Aggregation

Research on the influence of Compound I and comparators on platelets aggregation was carried out with a laser analyzer of platelet aggregation "Biola 230LA" (LLC "Biola", Russia). For aggregation inductor was used adenosine diphosphate (ADP) with a concentration of 20 [micro]g/ml and collagen - 5 mg/ml produced by "Technology-Standard" (Russia). Aggregatogram analysis was conducted using the AGGR software, taking into account the following indicators: General nature of aggregation (single-wave, two-wave; complete, partially reversible, irreversible), value of maximum aggregation (MA), maximum speed of aggregation (tg [alpha]), average size of platelet aggregates in relative units (mean radius aggregate).

Coagulation Component of Hemostasis

Study of influence of Compound I and comparator on coagulation component of hemostasis was conducted by widely accepted clotting tests on turbodimetric hemocoagulometer Solar CGL 2110 (CJSC "SOLAR", Belarus). The research included the indicators of activated partial thromboplastin time, thrombin time, prothrombin time, and A. Clauss fibrinogen concentration. Procoagulation activity of the substances under study in vitro was defined in concentration of [10.sup.-3] g'ml. The research applied reagents produced by "Technology-Standard" (Russia).

Thromboelastography (TEG)

TEG was carried out with apparatus TEG 5000 (Haemoscope Corporation, United States). The analysis of the thromboelastograms defined general tendency of coagulation (R), functional activity of platelets and fibrinogen (MA, Angle), activity of fibrinolysis clot lysis time (CLT), and the physicomechanical properties of the formed clots (G). For TEG activator was used 0.2 M CaCl2 ('Technology-Standard', Russia).

The Model of Parenhimatosis Hemorrhage in Rats

The experimental evaluation of the specific systemic hemostatic activity in vivo was carried out on viripotent male rats weighing 190-220 g. The drugs were injected intraperitoneally 1 h before parenhimatosis bleeding simulation. Then was midline laparotomy under ether anesthesia, delivering the front surface of the liver. The liver was resected using a special stopper (for the same volume, shape and size). The wound made had an elliptic shape with an area of 2.5 [cm.sup.2] and depth of 0.3 cm. The wound surface was tightly mopped with a gauze wad before the final hemostasis. The interference came amid registration of bleeding stop time and extent of blood loss. The amount of blood loss was determined by the gravimetric method, weighing the blood-soaked gauze material on electronic scales. [21]

Statistical Processing

The findings are processed using the statistical package Statistica 10.0 (StatSoft Inc., USA). The normality of the distribution of actual data was checked by using the criterion of Shapiro-Wilka. The groups were described using the median and interquartile interval. Variance analysis was performed using the criterion of Kraskel-Wallis test (for independent observations) and Friedman (for repeated observations). Critical level of P significance for statistical criteria was taken equal to 0.05.


Results of Studies In Vitro

The influence of Compound I and etamsylate on the hemostasis system in vitro was studied starting with TEG as a method that enables to evaluate the hemostatic system taken together on the main key units. The findings determined that the Compound I shows hemostatic properties exceeding level wise the values of etamsylate (Table 1). MA indicator, which characterizes the functional activity of platelets, in the presence of Compound I has been increased by 26.4% (P = 0.001) and by 13.8% (P = 0.001) compared to the control and etamsylate, respectively.

This leads to a statistically significant increase of the total coagulation potential toward hypercoagulation - the trimethylamine indicator reduced by 33.3% (P = 0.001) and 17.8% (P = 0.005) and triose-phosphate isomerase increased by 30.5% (P = 0.001) and 14.2% (P = 0.001) in comparison with the control and etamsylate. The values of the clot flowage increase - the E and G indexes increase in the group of Compound I by 1.3 times compared to the control. Etamsylate had no effect on indicators of the clot strength. Indicators that are responsible for fibrinolysis system (CLT, CL30, LY30), remain at the level of the stated values.

The findings on how Compound I and etamsylate influence functional activity of platelets in vitro are presented in Table 2. The research showed that the injection of 2 x [10.sup.-3] mol/l of Compound I into the aggregometer cuvet during 5 min of inductors makes platelet aggregation increase on average by 9.7% (P = 0.006) for ADP and 8.3% (P = 0.005) for collagen that two times exceeds etamsylate indicators. Analysis on "dose-effect" relationship shows that at a concentration of 5 x [10.sup.-4] mol/L of Compound I the platelet aggregation grows at an average by 2.3% for both inductors. Etamsylate in this concentration already shows no activity.

The findings on how Compound I and comparator influences plasma hemostasis component (Table 3) show that new benzylammonium salt and etamsylate do not change indicators of the coagulogram at concentrations of [10.sup.-3] g/ml.

Results of Studies In Vivo

The next stage examined the impact of Compound I and etamsylate on functional activity of platelets at intraperitoneal injection into rats (Table 4). Maximal platelet aggregation on injecting Compound I exceeded indicators of the control by more than 20%, and the values of etamsylate - by an average of 10%; platelet aggregation rate increased by 25.0% in respect to the control and by 15.5% in comparison with the etamsylate for both inductors of aggregation. The average radius of platelet aggregates in the presence of Compound I is higher the similar index in the control group by 40.0% and in the group of etamsylate - by 28.5%.

The findings of systemic hemostatic activity on the model of parenchymatous hemorrhage in rats are presented in Table 5. Table 5 data show that on intraperitoneal injection into rats the etamsylate reduced bleeding time by 26.5% (P = 0.0016) in comparison with the control group without significant impact on the total amount of blood loss. Compound I reduces the bleeding time by 37.4% (P = 0.003) and by 14.7% (P = 0.002) compared to the control and etamsylate, respectively. Wherein the blood loss volume reduced efficiently by 40.5% compared to the control (P = 0.002) and the group of etamsylate (P = 0.001).


The findings of the experimental work determined that the new benzylammonium salt shows proagregative activity that exceeds the values of etamsylate both in vitro and in vivo. There was no registered case of impact on coagulation component of hemostasis in vitro of the etamsylate and Compound I neither through the standard clotting tests nor through TEG. The Compound I activity data in vivo regarding spectrum-wise proagregate activity fully corresponds to the data obtained at the stage in vitro. The Compound I showed proagregate activity upon intraperitoneal injection to laboratory rats, being more effective than etamsylate, reducing the amount of blood loss and bleeding time.

Etamsylate (2.5-dihydroxibenzolsulphonatediethylamm onium salt) was developed in 1959 Esteve et al. and has been used as a hemostatic agent since1964. [22] The main domain of usage is to reduce menorrhagia and prevent/treat periventricular hemorrhage in children with low birth weight, as well as to control surgical or postsurgical capillary bleeding. In the year 1980, Vinazzer found that the etamsylate affects mechanisms of platelets adhesion and reduces capillary bleeding. [23] The research by Sack and Dujovne shows that etamsylate provokes agregation of platelets in platelet-enriched plasma, but such platelet aggregation is minor and reversible. [24] The study of biochemical prerequisites of pro-agregation effect of etamsylate helped to determine that it enhances platelet aggregation and ATP release induced by arachidonic acid, thromboxane A2, collagen and calcium ionophore A23187 but not ADP and/or adrenaline. [25] Based on the research findings, it was determined that injection of 2 x [10.sup.-3] mol/l of etamsylate in vitro induced spontaneous platelet aggregation, reaching an average of 22.1% relating to the control. Thus, the main effect of etamsylate falls on intact platelets, thereby potentially increasing the risk of blood clot formation, on the one hand, and remaining ineffective during non-capillary bleeding, on the other. [26-29] It should be noted that the Compound I did not cause spontaneous aggregation. This fact suggests that at the moment of induced aggregation the Compound I has a more selective effect on activated platelets and increases the overall hemostatic potential.


The findings reveal potentially high systemic hemostatic activity of benzylammonium salt 2-[3-methyl-1-N-propyl-7-(1,1-dioxothietanil-3) xantinyl-8-thio] acetic acid and convince of the need to further study this compound and its analogues to create on their basis highly efficient systemic selective hemostatic agents.


[1.] Council of Europe Publishing. Guide to the Preparation, Use and Quality Assurance of Blood Components. 13th ed. Strasbourg: Council of Europe Publishing; 2007.

[2.] Green B, Cairns S, Harvey R, Pettit M. Phytomenadione or menadiol in the management of an elevated international normalized ratio (prothrombin time). Aliment Pharmacol Ther. 2000;14(12):1685-9.

[3.] Charyshkin AL, Gafiullov MR, Dyomin VP. Surgical treatment of traumatic damages of parenchymatous bodies of an abdominal cavity. Creat Surg Oncol. 2012;1:81-3.

[4.] Shaposhnikov SA, Sinkov SV, Zabolotskikh IB. Perioperative prevention of thrombosis in patients with hemostasis disorders. Creat Surg Oncol. 2012;2:81-6.

[5.] Bindal J, Chhari A, Bhargava S. Trends of blood loss and blood transfusion during cesarean section - A retrospective study over 10 years. Int J Med Sci Public Health. 2017;6(6):1061-4.

[6.] Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, Garcia RC, et al. Treatment of warfarin-associated intracerebral hemorrhage: Literature review and expert opinion. Mayo Clin Proc. 2007;82(1):82-92.

[7.] Eeles A, Baikady RR. Peri-operative blood management. Indian J Anaesth. 2017;61(1):456-62.

[8.] Koshelev VN, Chalyk IV. CO2 and YAG lasers in the surgery of traumatic lesions of the liver, spleen and kidney. Vestn Khir Im I I Grek. 1992;149(7-8):52-6.

[9.] Ranucci M, Isgrd G, Soro G, Conti D. Efficacy and safety of recombinant activated factor vii in major surgical procedures: Systematic review and metaanalysis of randomized clinical trials. Arch Surg. 2008;143(3):296-304.

[10.] Patel AA, White CM, Coleman CI. Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention. Conn Med. 2007;71(2):93-5.

[11.] Ozogul Y, Baykal A, Onat D, Renda N, Sayek I. An experimental study of the effect of aprotinin on intestinal adhesion formation. Am J Surg. 1998;175(4):137-41.

[12.] Lethagen S. Desmopressin (DDAVP) and hemostasis. Ann Hematol. 1994;69(4):173-80.

[13.] O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126(1):11-28.

[14.] Makhija N, Sarupria A, Kumar Choudhary S, Das S, Lakshmy R, Kiran U. Comparison of epsilon aminocaproic acid and tranexamic acid in thoracic aortic surgery: Clinical efficacy and safety. J Cardiothorac Vasc Anesth. 2013;27(6):1201-7.

[15.] Dirkmann D, Radu-Berlemann J, Gorlinger K, Peters J. Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid. J Trauma Acute Care Surg. 2013;74(2):482-8.

[16.] Jaiswal M. Transfusion transmissible infections in blood donors at a tertiary care rural medical institute of Rohilkhand region, India. Int J Med Sci Public Health. 2017;6(1):195-200.

[17.] Kamilov FK, Timirhanova GA, Samorodova AI, Samorodov AV, Khaliullin FA, Murataev DZ. Antiagregation activity of new cyclohexilammonium salt on the basis of 1-ethylxantine in vitro. Kazan Med J. 2013;94:692-5.

[18.] Samorodov AV, Kamilov FK, Khaliullin FA, Shabalina YV, Khalimov AR, Murataev DZ, et al. The results of the preclinical studies of the new cyclohexilammonium salt 2-[3-methyl-7-(1.1-dioxothietanil-3)-1-etylxanthenyl-8-thio] acetic acid with reference to hemostasis system in vivo. Probl Biol Med Pharm Chem. 2016;8:10-7.

[19.] Samorodov AV, Kamilov FK, Khalimov AR, Klen YE, Khaliullin FA. The impact of the new potassium salt based on 3-thietanil-substituted triazole on hemostasis system. Biomedicine. 2016;3:59-67.

[20.] Kamilov FK, Timirhanova GA, Samorodov AV, Khalimov AR, Khaliullin FA, Gubaeva RA, et al. Salt [3-methyl-1-n-propyl-7-(1.1-dioxothietanil-3) xanthenyl-8-thio]acetic acid with proagregate activity. Patent for invention No 2459825RU, 31.05.2011.

[21.] Grif and C. Manual for Preclinical Studies of Medicaments. Part I. Moscow: Grif and C; 2012.

[22.] Esteve A, Canal J, Laporte J. Clinical study of the effect 141-E at the time of blood clotting and bleeding. Med Clin (Barc).


[23.] Vinazzer H. Clinical and experimental studies on the action of ethamsylate on haemostasis and on platelet functions. Thromb Res. 1980;19(6):783-91.

[24.] Sack ES, Dujovne I. Effects of cyclonamine on blood platelets. I. Turbidimetric and electronmicroscopic studies. Medicina (B Aires). 1973;33(5):525-35.

[25.] Okuma M, Takayama H, Sugiyama T, Sensaki S, Uchino H. Effects of etamsylate on platelet functions and arachidonic acid metabolism. Thromb Haemost. 1982;48(3):330-3.

[26.] Keith I. Ethamsylate and blood loss in total hip replacement. Anaesthesia. 1979;34(7):666-70.

[27.] Schulte J, Osborne J, Benson JW, Cooke R, Drayton M, Murphy J, et al. Developmental outcome of the use of etamsylate for prevention of periventricular haemorrhage in a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2005;90(1):F31-5.

[28.] Spahn DR. Severe bleeding in surgical and trauma patients: The role of fibrinogen replacement therapy. Thromb Res. 2012;130 Suppl 2:S15-9.

[29.] Elbourne DS. Randomised controlled trial of prophylactic etamsylate: Follow up at 2 years of age. N Y Acad Sci. 1987;205:9-13.

Aleksandr L Urakov (1), Aleksandr V Samorodov (2), Felix Kh Kamilov (2), Ferkat A Khaliullin (3), Regina A Gubaeva (3)

(1) Department of General and Clinical Pharmacology, Izhevsk State Medical Academy, Russia, (2) Department of Biological Chemistry, Bashkir State Medical University, Russia, (3) Department of Pharmaceutical Chemistry, Bashkir State Medical University, Russia

Correspondence to: Aleksandr V Samorodov, E-mail:

Received: May 11, 2017; Accepted: July 08, 2017

How to cite this article: Urakov AL, Samorodov AV, Kamilov FK, Khaliullin FA, Gubaeva RA. Hemostatical activity of new benzylammonium salt, 2-[3-methyl-1-n-propyl-7-(1,1-dioxotiethanyl-3)xantinyl-8-thio]acetic acid. Natl J Physiol Pharm Pharmacol 2017;7(11):1213-1218.

Source of Support: Nil, Conflict of Interest: None declared.

DOI: 10.5455/njppp.2017.7.0516408072017
Table 1: The indicators of TEG under the impact of Compound I and
etamsylate in vitro (n=7)

Indicator            Control               Etamsylate

R, min                11.6 (9.7-13.2)        8.7 (6.4-9.3) ([alpha])
Angle, deg            43.7 (42.4-44.3)      48.3 (44.5-49.1) ([beta])
MA, mm                55.9 (51.2-57.8)      60.1 (58.3-64.2) ([alpha])
TMA, min              35.4 (32.4-38.5)      28.7 (24.1-30.5) ([beta])
G, dyne/[cm.sup.2]     6.3 (5.7-6.4)         6.9 (6.2-7.3)
E, dyne/[cm.sup.2]   127.3 (115.4-142.3)   130.5 (121.7-134.3)
TPI/s                 14.1 (13.2-15.1)      16.2 (15.7-17.1) ([alpha])
CL30,%                97.5 (91.3-99.5)      95.3 (93.1-98.6)
LY30,%                 0.6 (0.2-0.9)         0.0 (0.0-0.0)
CLT, min              36.9 (32.4-38.3)      35.9 (34.6-37.3)
CI                     0.6 (0.3-1.3)         1.6 (1.4-1.8) ([beta])

Indicator            Compound I                     [P.sub.2]

R, min                 9.6 (8.9-10.3) ([alpha])     0.03
Angle, deg            57.4 (50.3-62.7) ([beta])     0.005
MA, mm                68.4 (64.1-74.7) ([beta])     0.001
TMA, min              23.6 (22.7-27.9) ([beta])     0.005
G, dyne/[cm.sup.2]     8.9 (8.1-9.4) ([beta])       0.006
E, dyne/[cm.sup.2]   140.1 (137.2-143.5) ([beta])   0.001
TPI/s                 18.4 (16.3-19.2) ([beta])     0.001
CL30,%                96.5 (94.8-99.4)              0.6
LY30,%                 0.0 (0.0-0.0)                0.4
CLT, min              34.7 (33.7-37.5)              0.5
CI                     2.5 (2.1-3.4) ([beta])       0.001

([alpha]) P<0.05; ([beta]) P<0.001 - Etamsylate or Compound I versus
control, [P.sub.2] - Etamsylate versus Compound I, MA: Maximum
aggregation, TEG: Thromboelastography, CI: Confidence interval, CLT:
Clot lysis time

Table 2: Indicators of ADP-and collagen-induced platelet aggregation
under the influence of etamsylate and Compound I in vitro in blood of
healthy donors (n=7)

Code number   Concentration    Spontaneous         Enhancement of
                  mol/L        aggregation of      ADP-induced
                               platelets (% to     platelet
                               the control)        aggregation (%
                                                   to the control)

Ethamsylate   2x[10.sup.-3]     22.1 (20.7-25.2)   3.7 (1.5-5.9)
              [10.sup.-3]       10.2 (7.4-13.5)    4.2 (2.1-6.3)
              0.5x[10.sup.-3]    2.9 (1.2-5.7)     0.0 (0.0-0.0)
Compound I    2x[10.sup.-3]      0.0 (0.0-0.0)     9.7 (7.4-12.3)
              [10.sup.-3]        0.0 (0.0-0.0)     7.2 (5.6-9.3)
              0.5x[10.sup.-3]    0.0 (0.0-0.0)     3.4 (2.7-4.2)

Code number   Enhancement of
              collagen-induced platelet
              aggregation (% to the

Ethamsylate   4.3 (2.2-6.9)
              5.3 (3.1-8.6)
              0.0 (0.0-0.0)
Compound I    8.3 (7.1-10.3)
              6.7 (5.4-8.1)
              3.9 (2.9-4.4)

P - Level of statistical significance of differences of etamsylate
groups versus Compound I, ADP: Adenosine diphosphate

Table 3: Influence of Compound I and etamsylate on loagulogram in vitro

Indicator       Control            Etamsylate         [P.sub.1]

APTT, s         23.1 (21.6-24.7)   23.4 (22.7-24.8)   0.7
TT, s           27.2 (26.4-28.9)   28.3 (27.5-29.6)   0.2
PT, s           12.4 (11.5-13.9)   12.9 (11.5-14.3)   0.3
Fibrinogen, s   24.3 (22.5-26.7)   25.9 (24.7-26.3)   0.2

Indicator       Compound I         [P.sub.2]   [P.sub.3]

APTT, s         21.9 (20.3-24.2)   0.6         0.7
TT, s           27.8 (26.3-28.9)   0.8         0.3
PT, s           13.2 (11.5-14.7)   0.4         0. 3
Fibrinogen, s   23.8 (22.3-24.8)   0.8         0.5

[P.sub.1] - Etamsylate versus control, [P.sub.2] - Compound I versus
control, [P.sub.3] - Etamsylate versus Compound I, APTT: Activated
partial thromboplastin time

Table 4: Indicators of ADP-and collagen-induced platelet aggregation in
rats following intraperitoneal injection of etamsylate and Compound I
into rats, n=7

Indicator               Control            Etamsylate

Collagen, mm            55.9 (53.8-58.1)   67.9 (64.2-69.3)
MRA (collagen)., r.u.    6.5 (6.2-6.7)      9.1 (7.8-11.4)
tg [alpha].(collagen)   36.5 (34.3-38.2)   37.2 (35.7-38.6)
ADP, mm                 54.1 (50.6-57.4)   67.1 (64.9-68.6)
MRA (ADP), r.u.          6.3 (6.2-7.1)      8.9 (7.2-10.3)
tg [alpha] (ADP)        42.7 (40.2-44.9)   46.4 (45.9-47.1)

Indicator               Compound I         [P.sub.2]

Collagen, mm            74.3 (70.2-77.9)   0.001
MRA (collagen)., r.u.   12.3 (11.7-13.5)   0.03
tg [alpha].(collagen)   44.2 (41.7-49.2)   0.004
ADP, mm                 77.6 (74.2-79.3)   0.004
MRA (ADP), r.u.         11.4 (8.1-9.3)     0.001
tg [alpha] (ADP)        53.4 (51.2-56.3)   0.006

[P.sub.1] - etamsylate or Compound I versus control, [P.sub.2] -
etamsylate versus Compound I, ADP: Adenosine diphosphate

Table 5: Indicators of hemostatic activity of etamsylate and Compound I
following intraperitoneal injection into rats (n=7)

Medicament          Control           Etamsylate        Compound I

Bleeding            97.9 (91.2-99.1)  71.9 (70.6-73.4)  61.3 (59.8-64.6)
time, s                               [P.sub.1]=0.0016  [P.sub.1]=0.003
[DELTA] weight of    7.6 (7.4-8.1)     6.9 (5.9-7.5)    4.1 (3.8-4.3)
drapes, g                             [P.sub.1]=0.23    [P.sub.1]=0.002

[P.sub.1] - etamsylate or Compound I versus control, [P.sub.2] -
etamsylate versus Compound I
COPYRIGHT 2017 Association of Physiologists, Pharmacists and Pharmacologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Urakov, Aleksandr L.; Samorodov, Aleksandr V.; Kamilov, Felix Kh.; Khaliullin, Ferkat A.; Gubaeva, R
Publication:National Journal of Physiology, Pharmacy and Pharmacology
Article Type:Report
Date:Nov 1, 2017
Previous Article:A mathematical approach in the management of hydrocephalus from tuberculous meningitis.
Next Article:Chronic ingestion of bisphenol A decreases the cholinergically evoked and spontaneous contractions of rat uterus in vitro.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |